Assessing Eligibility for Anticancer Drug Health Insurance Reimbursement Using Large Language Models: Benchmark Development and Comparative Study - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluating Anticancer Medication Insurance Reimbursement Eligibility Through Large Language Models: Development of Benchmarks and Comparative Analysis

  • By

  • Junhyuk Seo

  • Taerim Kim

  • Ju-Hyun Kim

  • June 15, 2026

Share

Original Source(s)

Assessing Eligibility for Anticancer Drug Health Insurance Reimbursement Using Large Language Models: Benchmark Development and Comparative Study

  • by Junhyuk Seo, Taerim Kim, Ju-Hyun Kim

  • June 15, 2026

Related Content

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy

Safety-Oriented Benchmarking of Large Language Models in Risk-Based Management of Abnormal Cervical Screening Results: Scenario-Based Benchmark Study